Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

Compare

5 Followers

2196 Stock Chart & Stats

HK$21.06

-HK$0.04(-0.30%)

At close: Jan 09 4:00 PM EST

HK$21.06

-HK$0.04(-0.30%)

Day’s Range― - ―

52-Week RangeHK$12.44 - HK$29.00

Previous CloseN/A

Volume1.35M

Average Volume (3M)8.63M

Market Cap

HK$78.48B

Enterprise ValueHK$78.32B

Total Cash (Recent Filing)HK$15.64B

Total Debt (Recent Filing)HK$32.21B

Price to Earnings (P/E)17.1

Beta1.14

Next Earnings

Mar 31, 2026

EPS Estimate

0.32

Next Dividend Ex-DateN/A

Dividend Yield1.57%

Share Statistics

EPS (TTM)0.34

Shares Outstanding551,940,500

10 Day Avg. Volume5,166,409

30 Day Avg. Volume8,626,817

Financial Highlights & Ratios

PEG Ratio0.76

Price to Book (P/B)0.75

Price to Sales (P/S)0.86

P/FCF Ratio530.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$29.49

Price Target Upside40.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Subsidiary Gains Approval for Ketoprofen Patch Clinical Trials

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an update. Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Zhaohui...

5d ago

Fosun Pharma’s Subsidiary Gains Approval for New Drug

An update from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical announced...

7d ago

Fosun Pharma Subsidiary Gains Approval for Innovative Cancer Drug Trial

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical announced that its...

14d ago

Fosun Pharma’s Subsidiary Gains Approval for Heparin Sodium Injection

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical announced...

15d ago

Shanghai Fosun Pharmaceutical Announces EGM Results and Director Election

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical announced...

15d ago

Shanghai Fosun Pharmaceutical Announces Board Composition and Committee Roles

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

15d ago

Fosun Pharma Announces Strategic Agreements with CQ Pharma and Fosun International

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has announced a...

19d ago

Fosun Pharma’s Pediatric Drug Application Gains Priority Review

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an update. Shanghai Fosun Pharmaceutical announced that its...

26d ago

Fosun Pharma’s Subsidiary Gains Approval for New Drug Application

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical announced that its...

29d ago

Shanghai Fosun Pharmaceutical Schedules 2025 Extraordinary General Meeting

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

1M ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

2y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

3y ago

SYNH

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$12.44 and its highest was HK$29.00 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$78.48B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Mar 31, 2026 which is in 104 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Oct 28, 2025. The company reported HK$0.341 earnings per share for the quarter, beating the consensus estimate of HK$0.33 by HK$0.011.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.35 which represents an annual dividend yield of 1.57%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.32.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.341 in its last earnings report, beating expectations of HK$0.33. Following the earnings report the stock price went down -2.79%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in HK:2196

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Outperform

Fundamentals

Return on Equity

6.75%

Trailing 12-Months

Asset Growth

4.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, is a leading healthcare conglomerate based in China. The company operates across various sectors, including pharmaceuticals, medical devices, healthcare services, and diagnostic products. Fosun Pharma is dedicated to the research, development, manufacturing, and marketing of pharmaceutical products and medical devices, aiming to improve health and well-being through innovation and quality.

Shanghai Fosun Pharmaceutical (Group) Co (2196) Earnings & Revenues

Historic Earnings Reports

2196 Stock 12 Month Forecast

Average Price Target

HK$29.49

▲(40.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"HK$12","18":"HK$18","24":"HK$24","30":"HK$30","36":"HK$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.299999995058,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$35.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.4852146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$29.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.49999999629,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$26.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18,24,30,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.38,22.450769230389078,23.521538460778153,24.592307691167232,25.663076921556307,26.733846151945386,27.80461538233446,28.87538461272354,29.94615384311262,31.016923073501694,32.08769230389077,33.15846153427985,34.22923076466893,{"y":35.299999995058,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.38,22.003478046153845,22.62695609230769,23.250434138461536,23.873912184615385,24.49739023076923,25.120868276923076,25.744346323076922,26.367824369230767,26.991302415384617,27.61478046153846,28.238258507692308,28.861736553846153,{"y":29.4852146,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.38,21.77384615356077,22.167692307121538,22.561538460682307,22.955384614243076,23.349230767803846,23.743076921364615,24.136923074925384,24.530769228486154,24.924615382046923,25.318461535607693,25.712307689168462,26.10615384272923,{"y":26.49999999629,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.589,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.743,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.692,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.634,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.634,"date":1696118400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.849,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.438,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.712,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.222,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >